The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2020

Filed:

Apr. 07, 2016
Applicant:

JO Cosmetics Co., Ltd., Ota-ku, Tokyo, JP;

Inventors:

Kanako Wada, Tokyo, JP;

Katsura Adachi, Tokyo, JP;

Assignee:

JO Cosmetics Co., Ltd., Ota-ku, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61K 8/44 (2006.01); A61Q 19/02 (2006.01); A61K 31/4172 (2006.01); A61K 31/4415 (2006.01); A61K 8/49 (2006.01); A61K 31/385 (2006.01); A61K 31/665 (2006.01); A61K 45/06 (2006.01); A61K 8/66 (2006.01); A61K 8/67 (2006.01); A61K 31/315 (2006.01); A61K 31/375 (2006.01); A61K 38/44 (2006.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 8/44 (2013.01); A61K 8/447 (2013.01); A61K 8/49 (2013.01); A61K 8/4946 (2013.01); A61K 8/4986 (2013.01); A61K 8/66 (2013.01); A61K 8/676 (2013.01); A61K 31/315 (2013.01); A61K 31/375 (2013.01); A61K 31/385 (2013.01); A61K 31/4172 (2013.01); A61K 31/4415 (2013.01); A61K 31/665 (2013.01); A61K 38/446 (2013.01); A61K 45/06 (2013.01); A61Q 19/02 (2013.01); Y02A 50/473 (2018.01);
Abstract

A tyrosinase activity inhibitor is prepared by combining (A) a metal (zinc, cobalt or iron) chelate compound of α-lipoyl amino acid or its pharmaceutically acceptable salt with (B-1) a human manganese SOD or (B-2) an ascorbic acid compound such as ascorbic acid and ascorbyl glucoside. A ratio (R1) of the (B-1) component content to the (A) component content is preferably 0.001 to 1,500, when R1 is defined as R1=[Unit concentration of (B-1) component (unit/mL)/Concentration of (A) component (μg/mL)], and a ratio (R2) of the (A) component content to the (B-2) component content is preferably 0.0001 to 1,000, when R2 is defined as R2=[Concentration of (A) component (m/mL)/Concentration of (B-1) component (mg/mL)]. An external preparation for skin contains the (A) component and the (B-1) component or the (B-2) component as effective ingredients for inhibiting tyrosinase activity.


Find Patent Forward Citations

Loading…